Real-world Effectiveness of Ustekinumab Versus Anti-TNF or Vedolizumab in Ulcerative Colitis: Induction and 12-Month Maintenance Results from the Prospective, Observational RUN-UC Study

Inflammatory Bowel Disease

Effectiveness of Ustekinumab for patients with moderate to severe Ulcerative Colitis: A Multi-Center Real-World Canadian Study

Am J Gastroenterol

Solitano V, Narula N, Ma C, Nanayakkara A, Suarez KE, Zoughlami A, Guizzetti L, Bessissow T, Jairath V

doi: 10.14309/ajg.0000000000003212

Inflammatory Bowel Disease

Tofacitinib versus Vedolizumab Among Bio-naïve Patients with Ulcerative Colitis: A Real-World Propensity-Weighted Comparison

J Crohns Colitis

Gros B, Constantine-Cooke N, Kennedy J, Elford AT, O'Hare C, Noble C, Jones GR, Arnott ID, Lees CW, Plevris N

doi: 10.1093/ecco-jcc/jjae188

Inflammatory Bowel Disease

Tofacitinib for ulcerative colitis in Brazil: a multicenter observational study on effectiveness and safety

BMC Gastroenterol

Parra RS, de Sá Brito Fróes R, Magro DO, da Costa Ferreira S, de Mello MK, de Azevedo MFC, Damião AOMC, de Sousa Carlos A, Barros LL, de Miranda MLQ, Vieira A, Sales MPM, Zabot GP, Cassol OS, Tiburcio Alves AJ Jr, Lubini M, Machado MB, Flores C, Teixeira FV, Coy CSR, Zaltman C, Chebli LA, Sassaki LY, Féres O, Chebli JMF

doi: 10.1186/s12876-025-03656-x

Inflammatory Bowel Disease

Real-World Treatment Persistence Among Advanced Therapy-Naïve or -Experienced Patients with Ulcerative Colitis Initiated on Ustekinumab or Adalimumab

Adv Ther

Zhdanava M, Kachroo S, Boonmak P, Burbage S, Shah A, Korsiak J, Lefebvre P, Kerner C, Pilon D

doi: 10.1007/s12325-024-02942-6

Inflammatory Bowel Disease

Deucravacitinib in Patients With Inflammatory Bowel Disease: 12-Week Efficacy and Safety Results From Three Randomized Phase 2 Studies in Crohn's Disease and Ulcerative Colitis

J Crohns Colitis

D'Haens G, Danese S, Panaccione R, Rubin DT, Peyrin-Biroulet L, Matsuoka K, Loftus EV Jr, Kobayashi T, Elsharkawi W, Miceli R, Ahmed S, Luo Y, Napoli A, Vaile J, Dornic Q, Patel A, Schreiber S

doi: 10.1093/ecco-jcc/jjaf080

Inflammatory Bowel Disease

Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial

Lancet Gastroenterol Hepatol

Choy MC, Li Wai Suen CFD, Con D, Boyd K, Pena R, Burrell K, Rosella O, Proud D, Brouwer R, Gorelik A, Liew D, Connell WR, Wright EK, Taylor KM, Pudipeddi A, Sawers M, Christensen B, Ng W, Begun J, Radford-Smith G, Garg M, Martin N, van Langenberg DR, Ding NS, Beswick L, Leong RW, Sparrow MP, De Cruz P

doi: 10.1016/S2468-1253(24)00200-0

Inflammatory Bowel Disease

Clinical outcomes after first-line anti-TNF treatment of patients with inflammatory bowel disease - a prospective multicenter cohort study

J Crohns Colitis

Zhao M, Larsen L, Dige A, Poulsen A, Lo B, Attauabi M, Dige Ovesen P, Wewer MD, Christiansen D, Hvas CL, Petersen AM, Bendtsen F, Seidelin J, Burisch J

doi: 10.1093/ecco-jcc/jjae192

Inflammatory Bowel Disease

Comparative risk of serious infection with vedolizumab vs anti-TNF in inflammatory bowel disease: results from nationwide Swedish registers

Am J Gastroenterol

Karlqvist S, Sachs MC, Eriksson C, Cao Y, Montgomery S, Ludvigsson JF, Olén O, Halfvarson J, SWIBREG Study Group

doi: 10.14309/ajg.0000000000002961

Inflammatory Bowel Disease

Health-Related Quality of Life Outcomes With Etrasimod Treatment in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From ELEVATE UC 52 and ELEVATE UC 12

Inflamm Bowel Dis

Armuzzi A, Rubin DT, Schreiber S, Panés J, Fellmann M, Bartolome L, Gruben D, Goetsch M, Bhattacharjee A, Chaparro M, Dubinsky MC

doi: 10.1093/ibd/izae229

Related content

Effectiveness of Ustekinumab for patients with moderate to severe Ulcerative Colitis: A Multi-Center Real-World Canadian Study

Tofacitinib versus Vedolizumab Among Bio-naïve Patients with Ulcerative Colitis: A Real-World Propensity-Weighted Comparison

Tofacitinib for ulcerative colitis in Brazil: a multicenter observational study on effectiveness and safety

Real-World Treatment Persistence Among Advanced Therapy-Naïve or -Experienced Patients with Ulcerative Colitis Initiated on Ustekinumab or Adalimumab

Deucravacitinib in Patients With Inflammatory Bowel Disease: 12-Week Efficacy and Safety Results From Three Randomized Phase 2 Studies in Crohn's Disease and Ulcerative Colitis

Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial

Clinical outcomes after first-line anti-TNF treatment of patients with inflammatory bowel disease - a prospective multicenter cohort study

Comparative risk of serious infection with vedolizumab vs anti-TNF in inflammatory bowel disease: results from nationwide Swedish registers

Health-Related Quality of Life Outcomes With Etrasimod Treatment in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From ELEVATE UC 52 and ELEVATE UC 12